BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...the specialty drug company licensed U.S., Canada and Mexico commercial rights to Onzentra Xsail, its sumatriptan...
BioCentury | Dec 21, 2018
Company News

Otsuka's Avanir to terminate Onzetra license

...it has received cash payments of $70 million under the deal. Onzetra is a low-dose sumatriptan...
...Japan Business: Drug delivery, Neurology Shannon Lehnbeuter Onzetra Xsail, sumatriptan nasal powder (avp-825, Intranasal sumatriptan powder, OptiNose sumatriptan) Avanir...
BioCentury | Nov 17, 2017
Clinical News

Promius reports Phase II data for DFN-02 in migraine

...between 2-24 hours post-dose (12.2% vs. 48.8%, p<0.001) vs. placebo. The intranasal spray formulation of sumatriptan...
...NYSE:RDY), Hyderabad, India Product: DFN-02 Business: Neurology Molecular target: NA Description: Intranasal spray formulation of sumatriptan...
BioCentury | Jun 20, 2016
Company News

Teva sales and marketing update

...Teva recalled all “pharmacy-level” inventory of migraine drug Zecuity sumatriptan in the U.S. and suspended sales...
...the application site. The company does not break out sales of the transdermal patch delivering sumatriptan...
BioCentury | May 23, 2016
Company News

Otsuka Pharmaceutical sales and marketing update

...Otsuka’s Avanir Pharmaceuticals Inc. subsidiary launched Onzetra Xsail sumatriptan nasal powder in the U.S. to treat...
...Inc. (Yardley, Pa.) granted Avanir exclusive, North American rights to develop and commercialize the low-dose sumatriptan...
BioCentury | Apr 25, 2016
Politics, Policy & Law

SCOTUS to the rescue?

...Juxtapid lomitapide from Aegerion [2] Eliquis apixaban from Bristol-Myers / Pfizer [1] Treximet naproxen / sumatriptan...
BioCentury | Feb 8, 2016
Clinical News

Onzetra Xsail sumatriptan nasal powder regulatory update

...FDA approved an NDA from Otsuka’s Avanir Pharmaceuticals Inc. subsidiary for Onzetra Xsail sumatriptan nasal powder...
...approved products. OptiNose granted Avanir exclusive, North American rights to develop and commercialize the low-dose sumatriptan...
...OptiNose Inc. , Yardley, Pa. Otsuka Pharmaceutical Co. Ltd. , Tokyo, Japan Product: Onzetra Xsail sumatriptan...
BioCentury | Feb 8, 2016
Clinical News

Zembrace SymTouch sumatriptan succinate regulatory update

...FDA approved an NDA from Dr. Reddy’s for Zembrace SymTouch sumatriptan succinate to treat acute migraine...
...without aura, in adults who are inadequately managed with existing treatment regimens. The product is sumatriptan...
...literature or previously approved products. Dr. Reddy’s Laboratories Ltd. (NYSE:RDY), Hyderabad, India Product: Zembrace SymTouch sumatriptan...
BioCentury | Nov 9, 2015
Clinical News

ZP-Triptan: Phase I data

...fast pain relief. The trial also consisted of an oral zolmitriptan arm and a subcutaneous sumatriptan...
BioCentury | Sep 14, 2015
Company News

Teva sales and marketing update

...Teva launched Zecuity sumatriptan in the U.S. for the acute treatment of migraine with or without...
...migraine with or without aura. The wholesale acquisition cost (WAC) for the transdermal patch delivering sumatriptan...
Items per page:
1 - 10 of 275